<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941221-0-00018</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> December 21, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Parts 520 and 556</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Animal Drugs, Feeds, and Related Products; Albendazole Suspension <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Final rule. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by SmithKline Beecham Animal Health Products. The NADA provides for use of albendazole suspension (Valbazen <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> ) as an anthelmintic in sheep. The regulations are also amended to establish a tolerance for albendazole residue in sheep liver. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> December 21, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Melanie R. Berson, Center for Veterinary Medicine (HFV&hyph;135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1643. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  SmithKline Beecham Animal Health Products, 1600 Paoli Pike, West Chester, PA 19380, filed NADA 140&hyph;934, which provides for oral use of a 4.55 percent albendazole suspension (Valbazen <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> ) as an anthelmintic in sheep. It is used for removal and control of: Adult liver flukes; heads and segments of common and fringed tapeworms; adult and fourth stage larvae of certain stomach worms (brown stomach worm, barberpole worm, and small stomach worm); adult and fourth stage larvae of certain intestinal worms (thread-necked intestinal worm, Cooper's worm, bankrupt worm, nodular worm, and large-mouth bowel worm); and adult and larval stages of lungworms.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The NADA is approved as of November 10, 1994, and the regulations are amended in 21 CFR 520.45a to reflect the approval. Additionally, the regulations are amended in 21 CFR 556.34 to establish a tolerance for albendazole residue in sheep liver. The basis for approval is discussed in the freedom of information summary. <!-- PJG 0012 frnewline --> In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and &sect;514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 3 years of marketing exclusivity beginning November 10, 1994, because the application contains reports of new clinical or field investigations (other than bioequivalence or residue studies) essential to the approval of the application and conducted or sponsored by the applicant. <!-- PJG 0012 frnewline --> The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 21 CFR Part 520 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animal drugs. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> 21 CFR Part 556 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animal drugs, Foods. <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and 556 are amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 520_ORAL DOSAGE FORM NEW ANIMAL DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 520 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority: <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 520.45a is amended by redesignating existing paragraphs (a) through (d)(3) as paragraphs (a)(1), (a)(2), (a)(3), (a)(4)(i), (a)(4)(ii), and (a)(4)(iii), respectively, and by adding new paragraph (b) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect; 520.45a  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Albendazole suspension. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Specifications <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The product contains 4.55 percent albendazole. <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sponsor <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . See No. 053571 in &sect;510.600(c) of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Related tolerances <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . See &sect;556.34 of this chapter. <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Conditions of use in sheep <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amount <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . 7.5 milligrams per kilogram of body weight (3.4 milligrams per pound). <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . For removal and control of the following internal parasites of sheep: Adult liver flukes ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Fasciola hepatica <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Fascioloides magna <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ); heads and segments of common tapeworms ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Moniezia expansa <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) and fringed tapeworm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Thysanosoma actinioides <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ); adult and fourth stage larvae of stomach worms (brown stomach worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Ostertagia circumcinta <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Marshallagia marshalli <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), barberpole worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Haemonchus contortus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), small stomach worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Trichostrongylus axei <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )); adult and fourth stage larvae of intestinal worms (thread-necked intestinal worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Nematodirus spathiger <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N. filicollis <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), Cooper's worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Cooperia oncophora <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), bankrupt worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Trichostrongylus colubriformis <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), nodular worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Oesophagostomum columbianum <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ), and large-mouth bowel worm ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Chabertia ovina <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )); adult and larval stages of lungworms ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Dictyocaulus filaria <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ). <!-- PJG 0012 frnewline --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Administer as a single oral dose using dosing gun or dosing syringe. Do not slaughter within 7 days of last treatment. Do not administer to ewes during first 30 days of pregnancy or for 30 days after removal of rams. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 556_TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. The authority citation for 21 CFR part 556 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority: <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Secs. 402, 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 342, 360b, 371). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 4. Section 556.34 is revised to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect; 556.34  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Albendazole. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Tolerances are established for residues of albendazole in uncooked edible tissues as follows: <!-- PJG 0012 frnewline --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Cattle <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The tolerance for the 2-aminosulfone metabolite (marker residue) in cattle liver (target tissue) is 0.2 part per million. The tolerance refers to the concentration of marker residue in the target tissue used to monitor for total drug residues in the target animals.  <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sheep <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The tolerance for the 2-aminosulfone metabolite (marker residue) in sheep liver (target tissue) is 0.25 part per million.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: December 13, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Stephen F. Sundlof, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Director, Center for Veterinary Medicine. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;31298 Filed 12&hyph;20&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            